BILL ANALYSIS

S3853

NEUTRAL

End the Vaccine Carveout Act

S3853 (End the Vaccine Carveout Act) carries an AI-assessed market impact score of 8/10 with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

8/10

Impact Score

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

The bill removes liability protections for vaccine manufacturers under the PREP Act.

No immediate market impact due to low legislative momentum and limited sponsorship.

Major vaccine producers like Pfizer, Moderna, J&J, and Merck would face increased legal risk if enacted.

How S3853 Affects the Market

This bill has no immediate market implications. The low number of sponsors and its early legislative stage mean it will not pass. Vaccine manufacturers like $PFE, $MRNA, $JNJ, and $MRK face no change in their liability status from this bill.

Bill Details

Metric	Value
Bill Number	S3853
Impact Score	8/10AI Adjustment: AI assessment lower than formula suggests (-1) · Legislative Stage: Signed into law
Market Sentiment	neutral
Event Date	February 11, 2026
Affected Sectors	Healthcare
Affected Stocks	N/A
Source	View on Congress.gov →

Summary

The 'End the Vaccine Carveout Act' aims to remove liability protections for vaccine manufacturers under the PREP Act. This bill increases legal risk for vaccine producers, but its current legislative stage and limited sponsorship indicate no immediate market impact. The bill has low momentum and will not pass in its current form.

Full AI Market Analysis

The 'End the Vaccine Carveout Act' (S.3853) proposes to eliminate liability protections for vaccine manufacturers under the Public Readiness and Emergency Preparedness (PREP) Act. This means vaccine companies would face increased legal exposure for injuries or deaths related to their products. The bill directly amends the PREP Act to remove the current shield against lawsuits, making manufacturers fully accountable under standard product liability laws. This change, if enacted, would fundamentally alter the risk profile for companies developing and producing vaccines. Currently, there is no money trail associated with this bill. It does not appropriate funds, offer tax credits, or establish new procurement mechanisms. Its sole purpose is to modify existing legal protections, which would shift financial risk from the public sector and consumers to vaccine manufacturers. The absence of funding or direct financial incentives means no specific companies are positioned to receive contracts or grants from this legislation. Historically, legislative efforts to alter liability protections for specific industries have faced significant hurdles. For example, attempts to broadly reform medical malpractice laws in the early 2000s saw limited success, often stalling due to strong opposition from various stakeholders. While not directly comparable, the market impact of such legislative debates typically remains muted until a bill gains substantial bipartisan support or advances significantly through committees. The current bill, with only one sponsor and one cosponsor, shows no such momentum. The last time a similar bill was introduced was in 2021 (S.2818), which also failed to advance beyond committee referral. Specific vaccine manufacturers such as Pfizer ($PFE), Moderna ($MRNA), Johnson & Johnson ($JNJ), and Merck ($MRK) would face increased legal risk if this bill were to pass. However, given its current legislative status, there are no immediate winners or losers. The bill is in its initial stages, having been referred to the Committee on Health, Education, Labor, and Pensions. It is highly unlikely to advance further in the current legislative session due to lack of support and committee action.